content_image/170264.jpg
## Pursuing Solutions in Immunology 

Elizabeth Menduke, 47 , lives outside Los Angeles, where she owns her own business. As a result of her psoriasis, she once had scaly red patches on more than 70  percent of her body. After treatment with STELARA ® (ustekinumab) for plaque psoriasis, Elizabeth says, “I am so very excited to have clearer skin again.” ® 

STELARA , a treatment approved for moderate to severe plaque psoriasis, is now available in more than 50  countries as a result of additional marketing approvals in 2010 . 

<img src='content_image/170264.jpg'>

Another treatment, SIMPONI ®  (golimumab), approved in 2009  for the treat- ment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, is now approved in approximately 40  countries. Two additional applications filed in 2010 seek to expand the U.S. label to include inhibition of the progression of structural damage in the treatment of rheumatoid arthritis and psoriatic arthritis. ® 

REMICADE  (infliximab), a treatment with 15  FDA approvals, also received addi- tional marketing approvals in 2010 , including several in Japan. In all, REMICADE ®  is available in 100  countries. 

Such incremental growth with existing products is an important strategy for the Immunology Therapeutic Area, which also expanded research and development capabilities 

into new treatment areas. In June, Centocor Ortho Biotech Inc. acquired RespiVert Ltd., a drug discovery company focused on developing inhaled small-molecule therapies for the treatment of pulmonary diseases. 

Sue Dillon, Ph.D., Global Therapeutic Area Head, Immunology, explains that the acquisition strengthens capabilities to further build a pipeline of novel oral and biologic therapies. 

“We’re focused on areas such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis and lupus,” says Dillon, “where we can continue to make a difference in patients’ lives.” 

CLEARER SKIN  Psoriasis once kept Elizabeth Menduke from feeling her best. But she has clearer skin after treatment with STELARA ®  for plaque psoriasis. 

## Targeting Diabetes 

Worldwide, 300  million people live with diabetes— almost equal to the entire U.S. population. 

“Diabetes is a far-reaching, complex disease,” says Martin Fitchet, M.D., Head of the Cardiovascular and Metabolism Therapeutic Area. “We are working to develop new treatment options that will not only help better manage the disease but have the potential to limit its progression.” 

In 2010 , a large clinical development program for canagliflozin* and new collaborations supported the Company’s commitment to build a portfolio of diabetes treatments. 

Canagliflozin is an investigational oral, selective sodium-glucose transporter- 2 (SGLT 2 ) inhibitor being studied in patients for the treatment of type 2 diabetes. The Phase III clinical trial program involves more than 10,000  patients. 

A new collaboration with Metabolex, Inc. focuses on discovering, developing and commercializing new treatment options for people with type 2  diabetes and obesity. An agreement was entered into with Diamyd Medical AB to support the development of pharmaceuti- cals targeting autoimmune diabetes and its complica- tions, in particular the treatment and prevention of type  1  diabetes. 

